...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biologics in Therapy >The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis
【24h】

The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis

机译：生物和小分子疗法在银屑病关节炎治疗中的作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The therapy of psoriatic arthritis (PsA) has blossomed in the past decade. Inhibition of tumor necrosis factor (TNF) has been at the fore of this approach and has paved the way for the investigation of many other potential pro-inflammatory and signaling pathways. Most of the initial studies of TNF inhibitors in PsA have been conducted in specific populations, largely focusing on those with established, peripheral joint disease. That said, in excess of 10?years’ worth of real world clinical experience has led to increased confidence in the wider use of these agents. We are now faced with an exciting time of discovery of many new molecules; these not only include new, large protein biological agents, but also smaller synthetic chemical molecules, many of which can be administered orally. Those currently under development are discussed within this article. Whilst there is scarce data about their real world efficacy and safety profile, it is evident that the therapeutic armamentarium for treating PsA will greatly increase in the foreseeable future and this is anticipated to improve patient outcomes.
机译：在过去的十年中，银屑病关节炎（PsA）的疗法蓬勃发展。抑制肿瘤坏死因子（TNF）一直是这种方法的重点，并为研究许多其他潜在的促炎和信号传导途径铺平了道路。 PsA中TNF抑制剂的大多数最初研究都是在特定人群中进行的，主要集中在那些已确诊的外周关节疾病的人群上。也就是说，超过10年的实际临床经验使人们对这些药物的广泛使用有了更大的信心。现在，我们面临着许多新分子被发现的激动人心的时刻。这些不仅包括新的大蛋白生物制剂，还包括较小的合成化学分子，其中许多可以口服。本文中讨论了当前正在开发的那些。尽管关于它们的实际疗效和安全性的资料稀少，但很明显，在可预见的将来，用于治疗PsA的治疗性武器装备将大大增加，并且有望改善患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号